HomeCompareLPMDF vs PFE

LPMDF vs PFE: Dividend Comparison 2026

LPMDF yields 33333.33% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 LPMDF wins by $36877558.99M in total portfolio value
10 years
LPMDF
LPMDF
● Live price
33333.33%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$36877559.04M
Annual income
$5,235,992,218,813.37
Full LPMDF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — LPMDF vs PFE

📍 LPMDF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLPMDFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LPMDF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LPMDF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LPMDF
Annual income on $10K today (after 15% tax)
$2,833,333.33/yr
After 10yr DRIP, annual income (after tax)
$4,450,593,385,991.36/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, LPMDF beats the other by $4,450,593,363,671.46/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LPMDF + PFE for your $10,000?

LPMDF: 50%PFE: 50%
100% PFE50/50100% LPMDF
Portfolio after 10yr
$18438779.55M
Annual income
$2,617,996,122,536.05/yr
Blended yield
14.20%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

LPMDF
No analyst data
Altman Z
0.4
Piotroski
7/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LPMDF buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLPMDFPFE
Forward yield33333.33%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%13.2%
Portfolio after 10y$36877559.04M$49.6K
Annual income after 10y$5,235,992,218,813.37$26,258.71
Total dividends collected$32285303.33M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: LPMDF vs PFE ($10,000, DRIP)

YearLPMDF PortfolioLPMDF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$1,677,367$1,666,666.67$9,153$693.39+$1.67MLPMDF
2$132,430,816$130,636,033.23$8,593$849.25+$132.42MLPMDF
3$4,961,292,770$4,819,591,797.06$8,336$1,066.78+$4961.28MLPMDF
4$89,681,348,983$84,372,765,719.75$8,437$1,384.80+$89681.34MLPMDF
5$808,641,040,801$712,681,997,389.07$9,013$1,875.40+$808641.03MLPMDF
6$3,868,109,904,567$3,002,863,990,909.25$10,306$2,680.72+$3868109.89MLPMDF
7$10,851,078,003,552$6,712,200,405,665.56$12,820$4,101.38+$10851077.99MLPMDF
8$20,409,489,435,000$8,798,835,971,199.81$17,673$6,826.70+$20409489.42MLPMDF
9$29,571,557,777,933$7,733,404,082,483.14$27,543$12,591.86+$29571557.75MLPMDF
10$36,877,559,041,202$5,235,992,218,813.37$49,560$26,258.71+$36877558.99MLPMDF

LPMDF vs PFE: Complete Analysis 2026

LPMDFStock

LMIR Trust is a Singapore-based real estate investment trust established with the principal investment objective of owning and investing, on a long-term basis, in a diversified portfolio of income-producing real estate in Indonesia that are primarily used for retail and/or retail-related purposes. LMIR Trust's current asset portfolio comprises 21 retail malls ("Retail Malls") and seven retail spaces located within other retail malls ("Retail Spaces", and collectively with the Retail Malls, the "Properties"). The Properties have a total net lettable area of 839,907 square metres and total valuation of Rp15,716.1 billion as at 31 July 2020, and are strategically located in major cities of Indonesia with large middle-income population. Tenants include leading names such as Matahari Department Store, Zara, M&S, H&M, Sogo, Giant, Hypermart, Carrefour, Ace Hardware, as well as international specialty tenants such as Victoria's Secret, Promod, McDonalds, Pizza Hut, Kentucky Fried Chicken, A&W, Fitness First and Starbucks.

Full LPMDF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this LPMDF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LPMDF vs SCHDLPMDF vs JEPILPMDF vs OLPMDF vs KOLPMDF vs MAINLPMDF vs JNJLPMDF vs MRKLPMDF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.